Unknown

Dataset Information

0

A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.


ABSTRACT: Huntington's disease (HD) is a progressive neurodegenerative disease caused by a glutamine expansion within huntingtin protein. The exact pathological mechanisms determining disease onset and progression remain unclear. However, aggregates of insoluble mutant huntingtin (mhtt), a hallmark of HD, are readily detected within neurons in HD brain. Although aggregated polyglutamines may not be inherently toxic, they constitute a biomarker for mutant huntingtin useful for developing therapeutics. We previously reported that the small molecule, C2-8, inhibits polyglutamine aggregation in cell culture and brain slices and rescues degeneration of photoreceptors in a Drosophila model of HD. In this study, we assessed the therapeutic potential of C2-8 in the R6/2 mouse model of HD, which has been used to provide proof-of-concept data in considering whether to advance therapies to human HD. We show that, at nontoxic doses, C2-8 penetrates the blood-brain barrier and is present in brain at a high concentration. C2-8-treated mice showed improved motor performance and reduced neuronal atrophy and had smaller huntingtin aggregates. There have been no prior drug-like, non-toxic, brain-penetrable aggregation inhibitors to arise from cell-based high-throughput screens for reducing huntingtin aggregation that is efficacious in preclinical in vivo models. C2-8 provides an essential tool to help elucidate mechanisms of neurodegeneration in HD and a therapeutic lead for further optimization and development.

SUBMITTER: Chopra V 

PROVIDER: S-EPMC2034257 | biostudies-literature | 2007 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.

Chopra Vanita V   Fox Jonathan H JH   Lieberman Greg G   Dorsey Kathryn K   Matson Wayne W   Waldmeier Peter P   Housman David E DE   Kazantsev Aleksey A   Young Anne B AB   Hersch Steven S  

Proceedings of the National Academy of Sciences of the United States of America 20071009 42


Huntington's disease (HD) is a progressive neurodegenerative disease caused by a glutamine expansion within huntingtin protein. The exact pathological mechanisms determining disease onset and progression remain unclear. However, aggregates of insoluble mutant huntingtin (mhtt), a hallmark of HD, are readily detected within neurons in HD brain. Although aggregated polyglutamines may not be inherently toxic, they constitute a biomarker for mutant huntingtin useful for developing therapeutics. We p  ...[more]

Similar Datasets

| S-EPMC4124458 | biostudies-literature
| S-EPMC3043604 | biostudies-literature
| S-EPMC6886799 | biostudies-literature
| S-EPMC4992622 | biostudies-literature
| S-EPMC4461140 | biostudies-literature
| S-EPMC5314343 | biostudies-literature
| S-EPMC3268004 | biostudies-literature
| S-EPMC5418739 | biostudies-literature
| S-EPMC2916705 | biostudies-literature
| S-EPMC6138304 | biostudies-other